Comparison between a β-tricalcium phosphate and an absorbable collagen sponge carrier technology for rhGDF-5-stimulated periodontal wound healing/regeneration.
BACKGROUND
The objective of this study is to compare a candidate β-tricalcium phosphate (β-TCP) carrier technology with the absorbable collagen sponge (ACS) benchmark to support recombinant human growth/differentiation factor-5 (rhGDF-5)-stimulated periodontal wound healing/regeneration.


METHODS
Routine, bilateral, critical-size (5-mm), 1-wall, intrabony periodontal defects were surgically created in the mandibular premolar region in 10 beagle dogs. Five animals received rhGDF-5/β-TCP and five animals received rhGDF-5/ACS, with a total of 20 μg rhGDF-5 per defect. The animals were euthanized for histologic and histometric analyses at 8 weeks postsurgery.


RESULTS
Both rhGDF-5/ACS and rhGDF-5/β-TCP stimulated the formation of functionally oriented periodontal ligament, cellular mixed fiber cementum, and woven/lamellar bone. Bone regeneration (height and area) was significantly greater for the rhGDF-5/β-TCP construct than for the rhGDF-5/ACS (3.26 ± 0.30 mm versus 2.22 ± 0.82 mm, P <0.01; and 10.45 ± 2.26 mm(2) versus 5.62 ± 2.39 mm(2), P <0.01, respectively). Cementum formation ranged from 3.83 ± 0.73 mm to 3.03 ± 1.18 mm without significant differences between groups. Root resorption/ankylosis was not observed.


CONCLUSIONS
The β-TCP carrier technology significantly enhanced rhGDF-5-stimulated bone formation compared with the ACS benchmark in this discriminating periodontal defect model. The structural integrity of the β-TCP carrier, preventing compression while providing a framework for bone ingrowth, may account for the observed results.
Department of Periodontology and Dentistry, National Health Insurance Corporation Ilsan Hospital, Seoul, Korea.
Young-Taek
YT
Kim
Ulf M E
UM
Wikesjö
Ui-Won
UW
Jung
Jung-Seok
JS
Lee
Tae-Gyun
TG
Kim
Chong-Kwan
CK
Kim
D016301:Alveolar Bone Loss / Q000473:pathology / Q000601:surgery*; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D001861:Bone Regeneration / Q000187:drug effects; D002130:Calcium Phosphates / Q000737:chemistry*; D025021:Cementogenesis / Q000187:drug effects; D003094:Collagen / Q000737:chemistry*; D004195:Disease Models, Animal; D004285:Dogs; D055428:Growth Differentiation Factor 5 / Q000627:therapeutic use*; D016557:Guided Tissue Regeneration, Periodontal / Q000379:methods*; D006801:Humans; D008297:Male; D008334:Mandible / Q000473:pathology / Q000601:surgery; D010012:Osteogenesis / Q000187:drug effects; D010513:Periodontal Ligament / Q000187:drug effects / Q000473:pathology; D011994:Recombinant Proteins; D013524:Surgical Flaps; D013997:Time Factors; D023822:Tissue Engineering / Q000379:methods; D054457:Tissue Scaffolds / Q000737:chemistry*
D002130:Calcium Phosphates; D055428:Growth Differentiation Factor 5; D011994:Recombinant Proteins; C485817:beta-tricalcium phosphate; D003094:Collagen